The U.S. Food and Drug Administration issued the second approvable letter for Vyvanse, Shire’s new ADHD medication currently under review for release in 2007. It is has not yet been determined by the FDA if Vyvanse will be classified as a schedule II controlled substance.

http://www.newratings.com/analyst_news/article_1447863.html

Last 5 posts by Dr. Theresa Cerulli

• American Heart Association Recommends EKG's - April 27th, 2008
• Prescribing Decisions May Depend on Genetic Tests - April 7th, 2008
• New Guidelines for Mental Health Treatment in Pre-schoolers - March 17th, 2008
• ADHD and Sleep - March 9th, 2008
• Through the Years with ADHD - February 17th, 2008

This entry was posted on Tuesday, December 26th, 2006 at 3:22 pm and is filed under Uncategorized, ADD Medication. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.